Moving Away from Spreadsheets: How to Know When It’s Time

July 23, 2018

The spreadsheet conundrum... Joe Smith, sales director for Great Start-Up Number 5 Billion and Thirty-One, puts on a blindfold and reaches out blindly for something, ANYTHING, to help him organize his team’s deals and commissions. He’s hopeful. He’s waiting. He knows he’ll come back with something. We’re talking metaphorically, of course. He’s not actually HOLDING a spreadsheet, he’s using Excel—because it’s the lowest hanging fruit. It’s free and easy to learn. And for a while, you know what? It works great. He can use VLOOKUPS and shortcuts to navigate. He can import booking results and activity metrics from Salesforce or his CRM. He can get so good at it that packaging complex algorithms becomes second nature.

Spotlight

Covance

As the drug development business of Laboratory Corporation of America Holdings (LabCorp) and the world’s most comprehensive drug development service company, we have helped pharmaceutical and biotech companies develop 49 of the top 50 prescription drugs in the marketplace today.

OTHER WHITEPAPERS
news image

Pharma R&D Annual Review 2022

whitePaper | May 5, 2022

welcome to pharmaprojects'2022 review of trends in pharmaceutical R&D for 30 year now, I've been taking an anual look at the evloution of pharma

Read More
news image

WILL PHARMA COMMIT TO DELIVERING AFFORDABLE THERAPEUTICS AGAINST COVID-19?

whitePaper | April 8, 2020

EPHA is a change agent – Europe’s leading NGO alliance advocating for better health. We are a dynamic member-led organisation, made up of public health civil society, patient groups, health professionals, and disease groups working together to improve health and strengthen the voice of public health in Europe.

Read More
news image

How IPD Can Deliver for Life Sciences

whitePaper | January 1, 2020

Life sciences is facing a number of disruptors: novel cell and gene therapies that will revolutionize manufacturing, drug delivery and pricing models; a battle for the best and brightest talent; political and public pressure on the price of medication as well as the implications of the fourth industrial revolution. These factors combine to make investment decisions more challenging. With life sciences firms placing an increasing focus on the most efficient use of capital and shorter delivery times, project delivery providers are striving to come up with leaner and more innovative strategies and solutions to meet these needs. Integrated Project Delivery (IPD) is one such strategy.

Read More
news image

The Next Generation of Rare Disease Drug Policy

whitePaper | April 7, 2022

The United States defines a rare disease as a condition affecting fewer than 200,000 people in the country or one in which “there is no reasonable expectation” of recovering research and development costs.1 Examples of rare diseases include genetically-linked cancers, cystic fibrosis, and debilitating pediatric conditions like Gaucher disease and spinal muscular atrophy

Read More
news image

Prescription Drug Pricing: How Lack of Transparency Reduces Market Access, Utilization, and Adherence

whitePaper | November 25, 2019

It's clear that healthcare prices weigh heavily on the minds of Americans, and the time has come for the pharmaceutical industry to take the reins of the prescription drug pricing dialogue with consumers.

Read More
news image

How Cellular is Enabling the Digital Supply Chain

whitePaper | January 12, 2020

Supply chains grow more and more complex every day. In response, manufacturers and shippers have been eagerly exploring digital tools that provide actionable insight into the location and condition of in-transit goods. Although there are many technology options when it comes to building a digital supply chain, one type of solution stands out as the most reliable and cost-effective: cellular.

Read More

Spotlight

Covance

As the drug development business of Laboratory Corporation of America Holdings (LabCorp) and the world’s most comprehensive drug development service company, we have helped pharmaceutical and biotech companies develop 49 of the top 50 prescription drugs in the marketplace today.

Events